封面
市場調查報告書
商品編碼
1087029

全球神經功能替代市場預測(2022-2027)

Global Neuroprosthetics Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球神經替代市場預計將從 2020 年的 32.08 億美元增長到 2027 年的 72.17 億美元,複合年增長率為 12.28%。

全球神經病變發病率的增加是預計在預測期內推動全球神經替代品市場增長的關鍵因素之一。此外,隨著糖尿病患者人數的增加和神經損傷患者人數的增加,預計未來幾年對神經功能替代品的需求將激增。此外,聽力受損人群的數量逐年顯著增加,預計未來幾年將激增,進一步推動全球神經替代市場在評估期內的增長。

本報告調查了全球神經功能替代市場,並提供了市場概況、市場驅動因素和限制、類型/技術/用途/區域分析、競爭形勢、公司概況等。

目錄

第1章介紹

  • 市場定義
  • 市場細分

第2章調查方法

  • 調查數據
  • 先決條件

第 3 章執行摘要

  • 調查重點

第4章市場動態

  • 市場促進因素
  • 市場製約因素
  • 波特五力分析
    • 終端用戶議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代威脅
    • 行業競爭形勢
  • 產業價值鏈分析

第 5 章全球神經功能替代市場分析:按類型

  • 簡介
  • 替代輸出神經函數
  • 輸入神經函數替代

第 6 章全球神經功能替代市場分析:按技術

  • 簡介
  • 深部腦刺激
  • 脊髓刺激法
  • □神經刺激法
  • 經顱磁刺激
  • 不明神經刺激

第 7 章全球神經功能替代市場分析:按應用

  • 簡介
  • 聽覺處理障礙
  • 帕金森病
  • 癲癇
  • 眼科疾病
  • 心血管疾病
  • 癱瘓
  • 阿爾茨海默病
  • 其他

第 8 章全球神經功能替代市場分析:按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印度尼西亞
    • 其他

第9章競爭環境與分析

  • 主要公司及戰略分析
  • 初創企業和市場優勢
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 10 章公司簡介

  • SenArs
  • LivaNova PLC
  • Medtronic PLC
  • Sonova Holding AG
  • Boston Scientific Corporation
  • Cochlear Ltd
  • Demant AS
  • Abbott Laboratories
  • NeuroPace, Inc.
  • BrainGate
  • NDI Medica
簡介目錄
Product Code: KSI061612097

The global neuroprosthetics market was evaluated at US$3.208 billion in the year 2020 and is projected to grow at a CAGR of 12.28% to reach a market size of US$7.217 billion by the year 2027.

Neuroprosthetics are devices that are implanted in patients having neural damage to compensate for and restore the normal functioning of the nerves, which consequently help in partially restoring normal bodily functions. The rising incidences of neurological disorders worldwide is one of the major factors anticipated to boost the growth of the global neuroprosthetics market during the forecast period. Furthermore, the growing number of diabetes patients, leading to nerve damage in many people, is also expected to lead to a surge in demand for neuroprosthetics in the coming years. Moreover, the number of people with disabling hearing loss has been increasing substantially over the years, and its projected rapid rise in the coming years is further anticipated to augment the growth of the global neuroprosthetics market during the assessment period.

The COVID-19 pandemic had a negative impact on the global neuroprosthetics market as access to healthcare was limited for non-COVID patients during the peak of the coronavirus outbreak. The focus of the healthcare system was shifted to COVID-19 patients due to a huge number of mortalities. This led to a decrease in the diagnosis and treatment of patients with disabling hearing loss, neurological disorders, and patients with other conditions requiring the use of neuroprosthetics. This led to a decrease in the demand for neuroprosthetics during the pandemic, which resulted in a decline in the market growth in 2020.

Rising cases of neurological disorders

The number of people suffering from neurological disorders is on the rise worldwide and is one of the prominent reasons anticipated to drive the demand for neuroprosthetics during the forecast period. According to World Health Organization, the number of deaths caused by neurological disorders has increased by nearly 39% in the last 30 years. It has also been stated that an increase in the number of patients with neurological disorders is being seen over the years, while the number of cases is further projected to grow in the coming years owing to a growing elderly population, a decrease in child mortality, and rise in the survival rate and life expectancy. As per data from the PAHO, the years lived with disability (YLDs) per 100,000 population in Brazil has increased from 784.06 years in 2010 to 813.74 years in 2019. In Mexico, it increased from 721.78 years in 2010 to 737.02 years in 2019. In the United States, the deaths from neurological disorders increased from 39.29 deaths per 100,000 population in 2010 to 47.39 deaths in 2019, witnessing an increase of more than 20%. The diseases such as Alzheimer's, dementia, and Parkinson's disease are some of the neurological disorders spreading fast. For instance, as per Pan America Health Organization, Canada has witnessed a surge in the disability-adjusted life years (DALYs) per 100,000 population from 351.30 in 2010 to 415.70 in 2019, growing by more than 18%.

Growing prevalence of hearing loss

As neuroprosthetics are used in severe hearing loss, the increasing prevalence of hearing loss worldwide is a significant factor expected to augment the growth of the global neuroprosthetics market in the coming years. According to data from the WHO, the absolute number of people with hearing loss in Brazil has increased from 10 million in 2008 to 13 million in 2018. In China, the number has increased from 74 million in 2008 to 96 million in 2018, while in India, the number of people with hearing loss increased from 76.5 million in 2008 to 100 million in 2018. WHO has projected that people with disabling hearing loss will increase from 430 million in 2020 to more than 700 million by 2050. This is expected to surge the demand for neuroprosthetics significantly.

North America projected to have a major market share

Geographically, the North American region is anticipated to hold a significant market share owing to the rising cases of neurological disorders in the region, especially in the United States. Furthermore, the presence of a quality healthcare system and its accessibility to the patients makes the diagnosis and treatment stronger, which is another prominent reason for the large market size of neuroprosthetics in the region. The Asia Pacific region is anticipated to witness substantial growth due to the rising prevalence of hearing loss in the region. According to data from the WHO, the absolute number of people with disabling hearing loss in South Asia is projected to increase from 131 million in 2018 to 176 million in 2030 and further to 267 million in 2050. Furthermore, the rapidly growing cases of diabetes in the region are leading to damage to the nerves and blood vessels of a large number of patients, which is further projected to surge the demand for neuroprosthetics in the Asia Pacific region during the assessment period.

Segmentation

  • By Type

Output Neural Prosthetics

Input Neural Prosthetics

  • By Technique

Deep Brain Stimulation

Spinal Cord Stimulation

Sacral Nerve Stimulation

Transcranial Magnetic Stimulation

Vague Nerve Stimulation

  • By Application

Auditory Processing Disorders

Parkison's Disease

Epilepsy

Ophthalmic Disease

Cardiovascular Disease

Paralysis

Alzheimer's Disease

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • UK
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Neuroprosthetics Market Analysis, by Type

  • 5.1. Introduction
  • 5.2. Output Neural Prosthetics
  • 5.3. Input Neural Prosthetics

6. Global Neuroprosthetics Market Analysis, by Technique

  • 6.1. Introduction
  • 6.2. Deep Brain Stimulation
  • 6.3. Spinal Cord Stimulation
  • 6.4. Sacral Nerve Stimulation
  • 6.5. Transcranial Magnetic Stimulation
  • 6.6. Vague Nerve Stimulation

7. Global Neuroprosthetics Market Analysis, by Application

  • 7.1. Introduction
  • 7.2. Auditory Processing Disorders
  • 7.3. Parkison's Disease
  • 7.4. Epilepsy
  • 7.5. Ophthalmic Disease
  • 7.6. Cardiovascular Disease
  • 7.7. Paralysis
  • 7.8. Alzheimer's Disease
  • 7.9. Others

8. Global Neuroprosthetics Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

  • 10.1. SenArs
  • 10.2. LivaNova PLC
  • 10.3. Medtronic PLC
  • 10.4. Sonova Holding AG
  • 10.5. Boston Scientific Corporation
  • 10.6. Cochlear Ltd
  • 10.7. Demant AS
  • 10.8. Abbott Laboratories
  • 10.9. NeuroPace, Inc.
  • 10.10. BrainGate
  • 10.11. NDI Medica